CAMP4 Therapeutics (CAMP) has entered into a strategic research, collaboration and license agreement with GSK (GSK) to identify and develop antisense oligonucleotide drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications. Under the terms of the agreement, CAMP4 will receive a $17.5 million cash upfront payment. Additionally, CAMP4 has the potential to receive additional payments for certain development and commercial milestones, in addition to tiered royalties on future product sales.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMP: